Cladribine

In the US, Cladribine (cladribine systemic) is a member of the drug class antimetabolites and is used to treat Hairy Cell Leukemia and Multiple Sclerosis.

US matches:

• Cladribine Novaplus
• Cladribine
• Cladribine Intravenous

UK matches:

• CLADRIBINE 1MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION (Leaflet)

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01BB04

CAS registry number (Chemical Abstracts Service)

0004291-63-8

Chemical Formula

C10-H12-Cl-N5-O3

Molecular Weight

285

Therapeutic Category

Cytostatic agent: Antimetabolite

Chemical Name

2-Chloro-2'-deoxyadenosine

Foreign Names

• Cladribinum (Latin)
• Cladribin (German)
• Cladribine (French)
• Cladribina (Spanish)

Generic Names

• Cladribine (OS: BAN, DCF, USAN, JAN)
• CdA (IS)
• Chlorodeoxyadenosine (IS)
• RWJ 26251 (IS)
• RWJ 26251-000 (IS)
• Cladribine (PH: BP 2016, Ph. Eur. 8, USP 38)
• Cladribinum (PH: Ph. Eur. 8)

Brand Names

• Ai Bo Ding
  Hisun Pfizer, China
• Biodribin
  Inst. Biotechn. i Antybiotykow, Poland
• Cladribine Agila
  Agila, Netherlands; Agila Specialties, Poland
• Cladribine Bedford
  Bedford, United States
• Hemobine
  Dosa, Argentina
• Intocel
  Sidus, Argentina
• Leustat
  Janssen Cilag, Argentina; Janssen-Cilag, Egypt; Janssen-Cilag, United Kingdom; Janssen-Cilag, Lebanon
• Leustatin
  Cilag, Hong Kong; Janssen, Australia; Janssen, Brazil; Janssen, Finland; Janssen, Lebanon; Janssen, Norway; Janssen, New Zealand; Janssen, Taiwan; Janssen, South Africa; Janssen Cilag, Netherlands; Janssen Pharmaceutical, Japan; Janssen-Cilag, Belgium; Janssen-Cilag, Switzerland; Janssen-Cilag, Germany; Janssen-Cilag, Greece; Janssen-Cilag, Italy; Janssen-Cilag, Portugal
• Leustatine
  Janssen-Cilag, France
• Litak
  Inter Farmacia Italia, Italy; Key Oncologics, South Africa; Lipomed, Austria; Lipomed, Belgium; Lipomed, Switzerland; Lipomed, Czech Republic; Lipomed, Germany; Lipomed, Denmark; Lipomed, Spain; Lipomed, France; Lipomed, United Kingdom; Lipomed, Hungary; Lipomed, Israel; Lipomed, Lithuania; Lipomed, Netherlands; Lipomed, Norway; Lipomed, Poland; Lipomed, Portugal; Lipomed, Romania; Lipomed, Serbia; Lipomed, Taiwan; Lipomed GmbH, Greece; Medifront, Finland; Medis Adria, Croatia (Hrvatska); Orphan, Australia
• Movectro
  Merck Serono, Australia

Glossary

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer